Truvada

(redirected from emtricitabine and tenofovir disoproxil fumarate)
Also found in: Dictionary.

Truvada

(tro͞o-vä′də)
A trademark for a drug consisting of a combination of emtricitabine and a prodrug of tenofovir.
References in periodicals archive ?
Sudam, "Development and validation of spectrophotometric methods for determination of emtricitabine and tenofovir disoproxil fumarate in bulk and tablet dosage form," International Journal of PharmTech Research, vol.
Emtricitabine and tenofovir disoproxil fumarate tablets are the genetic version of Gilead Sciences Inc.
Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naove adults.
Nasdaq: GILD) today announced full results from the second pivotal Phase 3 clinical trial (Study 103) of its Quad once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV.
Nasdaq: GILD) today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection, is non-inferior to Atripla([R]) (efavirenz/emtricitabine/tenofovir disoproxil fumarate) after 48 weeks of therapy in treatment-naove adults.
Lactic acidosis, usually associated with hepatic steatosis, has been reported with the use of nucleoside analogues, including emtricitabine and tenofovir disoproxil fumarate.
Food and Drug Administration (FDA) for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Complera combines three antiretroviral medications in one daily tablet - Gilead's Truvada([R]), which is a fixed-dose combination of the two nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir disoproxil fumarate, and Tibotec Pharmaceuticals' non-nucleoside reverse transcriptase inhibitor, rilpivirine (marketed as Edurant[TM] in the United States by Janssen Therapeutics, Division of Janssen Products, LP).
THRIVE (TMC278 against HIV, in a once-daily RegImen Versus Efavirenz), evaluated once-daily TMC278 (25 mg) compared to once-daily efavirenz (600 mg) combined with an investigator-selected background regimen consisting of two nucleoside reverse transcriptase inhibitors (abacavir and lamivudine, or emtricitabine and tenofovir disoproxil fumarate, or zidovudine and lamivudine).
Nasdaq:GILD) today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.
Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva[R] and Viread[R], respectively, and are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the tradename Truvada[R] for use as part of combination therapy.
Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva([R]) and Viread([R]), respectively, and are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the tradename Truvada([R]) for use as part of combination therapy.